

## Clinical Guidance:

Assessing whether COVID-19 patients will benefit from critical care, and an objective approach to capacity challenges

Endorsed by:

Royal College of Physicians (London)  
Scottish Intensive Care Society  
Welsh Intensive Care Society  
All-Wales Trauma and Critical Care Network  
National Critical Care Networks of England

## Executive summary

- This document is consistent with existing national guidance and lays out operational and ethical principles for decision-making during a pandemic.
- This guidance makes explicit reference to the different phases of a pandemic and introduces a revised CRITCON-PANDEMIC framework.
- Usual legal and ethical frameworks should continue to apply while capacity and NHS mutual aid are available (CRITCON-PANDEMIC levels 0-3), as is the case at time of writing.
- However by recognising the possibility of future conditions of resource limitation (CRITCON-PANDEMIC 4) and providing a structured approach, the guidance lays a responsibility on all NHS organisations to work together to avoid such conditions arising.
- Clinicians should focus on current clinical needs and should not treat patients differently because of anticipated future pressures. In making decisions they should work collectively with each other and with their organisations, and take into account all possible routes of escalation and mutual aid.
- In producing this guidance, we emphasise that all patients must be treated with respect and without discrimination, because everyone is of equal value.
- We acknowledge that COVID-19 is a new disease with a partial and evolving knowledge based, and aim to provide an objective clinical decision-making framework based on the best available information.
- It is recognised that a factual assessment of likely benefit may take into account age, frailty and comorbidities, but the guidance emphasises that every assessment must be individualised on a balanced, case by case, basis and may inform clinical judgement but not replace it.
- The effects of a comorbidity on someone's ability to benefit from critical care should be individually assessed. Measures of frailty should be used with care and should not disadvantage those with stable disability.
- A decision support aid is provided to support clinical judgement in the above setting.
- This document is released at a time when the first surge phase of the COVID-19 pandemic has substantially receded in the UK, although many ICUs remain under significant pressure. We believe that open publication of this guidance remains necessary, firstly to continue to ensure that nobody is denied appropriate treatment at any phase of the pandemic, and secondly to allow timely debate of the issues at a stage when there is available capacity but the future course of events remains unpredictable.

## 1. Principles

The primary aim of this guidance is to ensure that all patients get appropriate treatment during the pandemic. The immediate clinical guidance is intended to be consistent with national guidance issued by the RCP, BMA and GMC<sup>1,2,3</sup>. Where clinicians can document that they have considered and applied national professional guidance, including the present document, this will provide strong evidence that they have acted lawfully and according to their professional obligations.

If we are to minimise the harm that the virus can cause, patients should receive the interventions that are most likely to benefit them. The first responsibility of clinical teams is to assess what treatment is likely to provide benefit to the patient, taking into account the best available opinion on factors that predict this and applying it to the specific situation of the patient they are treating. COVID-19 is a new disease and data to assist clinical teams assessing what interventions are likely to benefit patients are now emerging. Some of the tools and discussion in this guidance are specific to COVID-19, but the ethical principles apply to all patients including non-infected patients who may be indirectly affected by the pandemic due to changes in delivery of normal services.

A decision on the appropriateness of a specific treatment is not concerned with **whether** patients will receive treatment, but with **what** treatment should be offered. If it is decided that one treatment plan is not appropriate, other more appropriate treatments will be started or continued. For some patients End-of-Life Care is appropriate, either because that is their preferred option or because the clinical team has assessed their prognosis and has concluded that an intervention will not bring them benefit. Such decisions are based on the patient's circumstances and are independent of resource availability.

Decision making should be consistent with current ethical and legal frameworks<sup>4</sup>. Patients' preferences in relation to the intrusiveness of treatment that is acceptable to them must be taken into account. They should be supported to record their wishes around treatment escalation if their condition deteriorates, including cardiopulmonary resuscitation (which can be undignified and intrusive with limited chances of success). However, patients are not entitled to demand care that is clinically inappropriate.

The immediate clinical guidance for critical care emphasises that usual pre-existing ethical and clinical decision-making models and protocols will continue to be applied by clinicians and others, other than in the extreme circumstances arising under CRITCON-PANDEMIC-4 as described in Appendix 1. It also emphasises that all decision-makers, whether clinical or managerial, are obliged to communicate and act so as to avoid CRITCON-PANDEMIC-4 arising at any individual hospital. To date there has proved to be capacity within the NHS.

<sup>1</sup> Ethical dimensions of COVID-19 for frontline staff, Royal College of Physicians, 7 April 2020 <https://www.rcplondon.ac.uk/file/20726/download>

<sup>2</sup> COVID-19 – ethical issues. A guidance note, and Statement/briefing about the use of age and/or disability in our guidance, British Medical Association, updated 9 Apr 2020 <https://www.bma.org.uk/advice-and-support/covid-19/ethics/covid-19-ethical-issues>

<sup>3</sup> Coronavirus: your frequently asked questions. General Medical Council, <https://www.gmc-uk.org/ethical-guidance/ethical-hub/covid-19-questions-and-answers>

<sup>4</sup> NICE COVID-19 rapid guideline: critical care in adults (NG159), Updated 9 April 2020 <https://www.nice.org.uk/guidance/ng159>

The guidance necessarily recognises however that there is precedent for the use of objective clinical criteria in specific and limited circumstances, both in normal circumstances<sup>5</sup> and during national emergencies<sup>6</sup>. It also recognises that should CRITCON-PANDEMIC-4 be engaged clinicians will need to act according to national ethical and clinical decision-making criteria, and provides the necessary clinical criteria in relation to allocation of limited resources between patients. As understanding of COVID-19 evolves the clinical criteria may be adjusted.

There is clear demand for such clinical guidance in conjunction with associated ethical guidance. It is intended to provide practical support and clear protocols for clinicians to apply and to support them accordingly. It promotes understanding by the public as to the clinical and ethical considerations that will be applied. It may be revised as part of the continuing review of international and national data as to COVID-19 and wider contributions from other stakeholders.

<sup>5</sup> Introduction To Patient Selection and Organ Allocation Policies, NHSBT POLICY POL200/4.1 <https://www.odt.nhs.uk/transplantation/tools-policies-and-guidance/policies-and-guidance/>

<sup>6</sup> Guidance and triage tool for the rationing of blood for massively bleeding patients during a severe national blood shortage, National Blood Transfusion Committee, <https://www.transfusionsguidelines.org/uk-transfusion-committees/national-blood-transfusion-committee/responses-and-recommendations> (updated 6 April 2020)

## 2. A structured approach to assessing when critical care is an appropriate option

Some treatments, such as critical care, are never certain to bring benefits to any one individual and should be approached as a ‘trial of therapy’. Admission for critical care is appropriate if the patient can be reasonably expected to survive and receive sustained benefit. Continuation should be considered in the light of patient response. The desired or likely outcomes of treatment should be discussed at the start. There should be regular review. If the goals are not being achieved, other treatment options should be considered, including transition to end of life care<sup>7,8</sup>.

The clinical support materials included in this document are designed to operationalise and support existing guidance, and to make the best available information accessible to clinicians in a clear and straightforward way to support their professional judgment. The clinical support materials include a Decision Support Aid which summarises key data on factors that are likely to impact on the chances of patients surviving to be discharged from critical care. They should ensure that there is a comprehensive, individualised assessment of each patient.

At all stages short of in *extremis* resource limitation (CRITCON-PANDEMIC-4), they should be used only for individualised decision-making, independent of resource. If a situation of limited resources is reached (CRITCON-PANDEMIC-4, agreed at regional or national level and only after maximum escalation and mutual aid), then they may come into use as an appropriate objective clinical way to individually assess and allocate the resource according to those patients most likely to benefit. This approach is consistent with the published national ethical guidance and is directed at minimising the overall loss of life. It is emphasised that at no stage is a numeric score or threshold applied: *each patient will continue to be considered as an individual*.

Patients’ underlying health may significantly affect their ability to benefit. It is important to assess this in a non-discriminatory way. In a clinically appropriate context, frailty (accumulated cellular damage and diminished biological reserve) and age may be relevant indications of capacity to benefit from critical care and other invasive therapies. They must be objectively and individually assessed as part of wider clinical judgement, taken within the context of a wider assessment of health over the previous few months. Although there are established tools to characterise frailty, care should be taken to make individual assessments in the event of stable disability, developmental disorders or established stable long-term organ support (e.g. respiratory or renal). These are discussed further below.

The explanation of the principles within this framework has been informed by the work from the DHSC Moral and Ethical Advisory Group<sup>9</sup>, medical Royal Colleges, the British Medical Association, clinical specialist societies and local guidance within the NHS. Our aim is to ensure that all patients are treated with respect, as everyone matters equally.

<sup>7</sup> Treatment and care towards the end of life: good practice in decision making.  
<https://www.gmc-uk.org/ethical-guidance/ethical-guidance-for-doctors/treatment-and-care-towards-the-end-of-life>

<sup>8</sup> Care at the end of life: A guide to best practice, discussion and decision-making in and around critical care Faculty of Intensive Care Medicine, <https://www.ficm.ac.uk/critical-futures-initiative/care-end-life>

<sup>9</sup> <https://www.gov.uk/government/groups/moral-and-ethical-advisory-group>

### 3. Critical care capacity and decision-making: organisational & Individual responsibilities

To date, and reflecting a strategy of significantly increasing capacity, CRITCON-PANDEMIC-4 has not been reached at any individual hospital, although at the cost of significant adaptation to usual standards of staffing and equipment and with so far unknown impact on outcomes. The demands made of individual hospitals have varied regionally, with the possibility of further secondary hot spots after initial control or in the event of further waves of pandemic. The immediate guidance addresses the possibility of overwhelming demand in future.

*It is important that while there is capacity and access, usual decision-making should apply equitably, and this document aims to reinforce that. Patients should not suffer either from geographical inequality of access, or from premature and incorrect resort to resource-limited decision-making at individual sites. It is equally important that frontline clinicians are fully engaged and supported by their Trusts, Regional Medical Teams and wider NHS, so that no one is avoidably put in a position of clinical decisions being affected by local resource limitation when this can be effectively addressed by NHS mutual aid. Common and agreed national guidance is required to assess, manage and share knowledge of critical care capacity by each of these parties.*

The CRITCON classification for Winter Influenza Surge was designed in 2009 to describe pressure on intensive care units in a qualitative and easy to understand way. It is explicitly designed to represent the level of “stress” in the system, and any deviation required from usual practice, reflecting innovative practices and flexible expansion. It is based on the actual clinical capacity of the system as assessed on the ground, rather than simple bed and occupancy numbers or other quantitative measures - which may not adequately reflect available staffing, equipment or consumables. Should other critical care interventions be found to be beneficial in the context of COVID-19 (such as CPAP or renal replacement therapy) and dedicated beds are needed for those treatments, they should be included in the assessment of bed capacity to define the CRITCON status.

The CRITCON-PANDEMIC matrix (Appendix 1) applies the 2009 – 2014 criteria to the specific COVID-19 pandemic. Obligations and expectations of organisations and individuals are reflected at each level of demand on resources in an objective and practical form. The central objective is to define and co-ordinate a response across the NHS such that individual Trusts maintain levels up to CRITCON-PANDEMIC-2 (‘Sustained Surge’) throughout the pandemic. Meeting this objective would mean that CRITCON-PANDEMIC levels 3 and (most particularly) 4 are not engaged.

In order to achieve this, a deteriorating CRITCON-PANDEMIC level must lead to a whole-hospital, Network/ODN, Regional and (when necessary) national response with the aim of returning critical care to lower levels of CRITCON as quickly as possible, whilst ensuring safe and equitable care for all during times of peak demand. Especially important is the explicit use of maximal mutual aid to prevent any hospital reaching CRITCON-PANDEMIC-4, when there is a risk of resource-limited decisions arising.

Individual clinicians and teams have a vital part to play in this process by ensuring that they are fully engaged with data reporting processes and have escalated concerns and information within their organisations rapidly and reliably. The CRITCON-PANDEMIC reporting system is designed to supplement numeric reporting systems and be clinician-friendly, accurate and easily interpretable.

The declaration of CRITCON-PANDEMIC level for a given critical care unit remains the responsibility of an individual Trust / Health Board, in coordination with regional and national organisations, including the Critical Care Networks and NHS England. The operational details of accurately reporting capacity within a given region are an NHS command chain responsibility, and we suggest that the responsibility for accurately assessing unit strain through CRITCON-PANDEMIC and applying mutual aid to minimise the duration of CRITCON-PANDEMIC-3 and prevent CRITCON-PANDEMIC-4 should rest with the relevant Regional Medical Director.

## 4. Ethical practice when critical care capacity is stretched (CRITCON-PANDEMIC-4 only)

Clinical teams should focus on current clinical demands and available resources. They should not, at any stage of escalation, treat patients differently because of anticipated future pressures, since at every stage short of CRITCON-PANDEMIC-4, mutual aid of some form should be available. If they consider that they do not have the resources to provide the care that they believe would be most likely to benefit the patient, they should consider whether that care may reasonably be provided at another site (if the patient's condition would enable a transfer) within their regional network or nationally, or by distribution of resources from another site. This assessment should involve clinical colleagues and senior operational management, and it should be borne in mind that under these circumstances and with appropriate escalation, access to extraordinary transport and other measures are likely to be available, under civil powers or military assistance to same.

Individual clinical staff should not be required to take decisions on potentially life-sustaining treatments alone under conditions of resource limitation. This is an unfair burden to ask any individual to bear. Employers should take steps to support ethical decision-making, including through clinical ethics committees and psychological support.

Consistent with published ethical guidance, clinical decisions will be taken according to the assessment of which patients are most likely to benefit from treatment applying limited resources. This approach is both transparent and objective. It does not create arbitrary clinical thresholds in relation to any individual patient, but does ensure that limited resources are directed at achieving the highest levels of survival across the population group of patients.

It is recognised that in critical care clinical decision-making sometimes requires an immediate decision without the opportunity for consultation. Where practicable, however, all clinical decisions under the extreme circumstances engaged under CRITCON-PANDEMIC-4 should be taken collectively by a team of qualified practitioners applying the relevant ethical and clinical guidance, and - where necessary and practicable - reference made by them to local ethical guidance committees. The rationale for such decisions should be clearly documented, including any process of consultation<sup>10</sup>.

<sup>10</sup> [www.criticalcarenice.org](http://www.criticalcarenice.org)



## 5. Use of this guidance

It is important to use all materials in the context of the written narrative above, and in the context of clinical judgement and individualised decision making.

In Appendix 1, the CRITCON-PANDEMIC operational responsibility matrix sets decision-making into an operational escalation context and recognises that individualised decision making, and existing recognised best practice, should be maintained through escalating levels of demand.

Effective expansion and sharing of resources should ensure that conditions of triage should not need to be considered until a situation of regional and national *extremis*. This point must be determined externally by the declaration of CRITCON-PANDEMIC-4 by a given Trust in coordination with regional and national structures, and not determined by an individual clinician. Even at this extreme point there should be an equitable and transparent decision-making process.

Appendix 2 contains a Decision Support Aid to guide prognostication in a resource-limited setting. Patients' comorbidities, frailty and age **may** be relevant indications of capacity to benefit from critical care and other invasive therapies as outlined by NICE<sup>11</sup>. This graphic summarises available data on COVID-19, and highlights those factors that are known to decrease the benefits of critical care. Decision-making based on prognostic indicators should take place in a recognised framework.

The first iteration for the Decision Support Aid was developed by a clinical expert group from UK advanced respiratory support centres. It was based on a comprehensive review of the available literature and data. Further relevant data is progressively becoming available and is reflected in the guidance. The guidance is based on continuing review and consultation with an extended, multi-Trust group of acute medicine and respiratory clinicians, including from Scotland. Available outcome data have been drawn from the Intensive Care National Audit & Research Centre (ICNARC), while acknowledging that these are constrained by the evolving nature of the source data emerging during the pandemic, and potential biases arising from this.

There are some important caveats to the use of clinical frailty indices. Frailty is a distinctive health state related to the ageing process, in which multiple body systems gradually lose their in-built reserves. Around 10 per cent of people aged over 65 years have frailty, rising to between a quarter and a half of those aged over 85<sup>12</sup>. Frailty is assessed using proxy measures including the degree of home carer and other support required. These measures should not be routinely used to assess patients who may have good biological reserve to recover from acute illness have stable physical disabilities, learning disabilities or autism, or with long-term organ support needs (examples may include stable dialysis patients, or those needing long-term respiratory or other support for neurodisability such as genetic muscle disease or cerebral palsy).

<sup>11</sup> <https://www.nice.org.uk/guidance/ng159>

<sup>12</sup> <https://www.bgs.org.uk/resources/introduction-to-frailty>

An individualised assessment of frailty in such cases should include clinical stability and rate of deterioration of functional status. The severity of chronic disease is important when considering the ability of such patients to recover from multiple organ failure and prolonged mechanical ventilation.

Patients receiving organ support for long-term conditions should be aware that they may not be admitted to the hospital where their care is usually delivered and therefore consideration should be given to formulating an Emergency Health Care Plan with patient participation.

## Appendix 1. Capacity Management: CRITCON-PANDEMIC Levels

This is a significant adaptation of language and concept from existing CRITCON-WINTER definitions

The CRITCON-PANDEMIC matrix allows available resources to be fairly reflected in individualised decision making, and if applied correctly **prevents** inappropriate recourse to triage whilst resources are available, maintaining existing legal and ethical best practice.

CRITCON-2020	Definition	Organisational Responsibility (Trust/Health Board, Network, Region)	Clinician responsibility	
<b>0 – NORMAL</b>	Able to meet all critical care needs, without impact on other services.  Normal winter levels of non-clinical transfer and other 'overflow' activity.	Routine sitrep reporting  Match critical care capacity to demand.  Consistent implementation of legal and professional best practice.		Usual legal and ethical frameworks
<b>1 PREPARATORY</b>	Significant expansion/multiplication of bed capacity, supported by extensive redeployment of staff and equipment from other areas.	Plan and make physical preparation for large-scale critical care expansion.  Prioritisation and reduction of elective work.  Identify regional mutual aid systems and patient flows.  Ensure good awareness of and engagement with local capacity reporting mechanisms including CRITCON  Build resilience in data collection and research capacity.		
<b>2 SUSTAINED SURGE</b>	System at full stretch, both in ventilator capacity and/or staffing levels, with staff working outside usual role. but adherence to usual clinical practice goals wherever possible  Other resources may be becoming limited e.g. oxygen, renal replacement therapy.	Mutual regional aid in place and active.  Escalate and ensure maximum awareness of 'hot spots' at regional and national level.  CRITCON 2 should be the target state during the high-intensity stage of the pandemic. Units still in CRITCON 1 may need to step up to CRITCON 2 to aid others and minimise the occurrence of CRITCON 3.  Ensure good governance and support for clinical staff working flexibly.  Ensure rapid data collection and research participation.	Apply usual ethical and legal principles.  Use Decision Support Aid (Appx 2) to assess benefit.  Apply existing best practice in implementation, discussion and documentation  Deliver best available care both to infected patients, and non-infected patients indirectly affected by changes to normal services.	
<b>3 SUPER SURGE</b>	Some resources starting to be overwhelmed.  Full use of stretched staffing ratios and cross-skilling.  Delivery of best available care but not usual care, for the majority of patients.	Whole hospital response.  Active decompression of hot sites.  High-volume transfers within and across regional boundaries.  Maximum co-ordinated effort to prevent any individual site progressing to CRITCON 4	Lead and participate fully in reporting, shared awareness of the evolving situation, data collection, and research.	
<b>4 CODE RED: TRIAGE RISK</b>	Services overwhelmed and delivery of critical care is resource limited.  This stage should never be reached at any site unless regionally & nationally recognised and declared.	Full engagement between clinical frontline, Trust/Health Board, Region and national/political leadership, under 12 hourly review.	Focus on <b>minimising loss of life</b> .  Use Decision Support Aid to assess benefit and prioritise	

**Shared operational/clinical responsibility**

# Appendix 2 – COVID-19 Decision Support Aid

Only valid if used as part of ‘Clinical Guidance: assessing whether COVID-19 patients will benefit from in critical care, and an objective approach to capacity challenges’, ICS 2020.

## COVID-19 DECISION SUPPORT AID

AGE	Decreasing likelihood of benefit
16-39	
40-39	
50-59	
60-69	
70-79	
80+	

  

CLINICAL FRAILTY SCALE	Decreasing likelihood of benefit
<b>VERY FIT</b> - people who are robust, active, energetic, and motivated. These people commonly exercise regularly. They are amongst the fittest for their age.	
<b>WELL</b> - people who have no active disease symptoms but are less fit than category 1. Often, they exercise or are very active occasionally (e.g. seasonally)	
<b>MANAGING WELL</b> - people whose medical problems are well controlled, but are not regularly active beyond routine walking.	
<b>VULNERABLE</b> - while not dependent on others for daily help, often symptoms limit activities. A common complaint is being 'sloved up', and being tired in the day.	
<b>MILDLY FRAIL</b> - these people often have more evident slowing, and need help in high order IADLs (finances, transportation, heavy housework, medications). Typically, mild frailty progressively impairs shopping and walking outside alone, meal preparation and housework.	
<b>MODERATELY FRAIL</b> - people who need help with all outside activities and with keeping house. Inside, they often have problems with stairs and need help with bathing and might need minimal assistance (cuing, standby) with dressing.	
<b>SEVERELY FRAIL</b> - completely dependent for personal care, from whatever cause (physical or cognitive). Even so, they seem stable and not at high risk of dying (within ~ 6 months).	
<b>VERY SEVERELY FRAIL</b> - completely dependent, approaching end of life. Typically, they could not recover even from a minor illness.	
<b>TERMINALLY ILL</b> - approaching the end of life. This category applies to people with a life expectancy <6 months, who are not otherwise evidently frail.	

  

CO-MORBIDITY in six months prior	One or more = less likelihood of benefit
<b>CARDIAC ARREST</b> from any cause in last 3 years	
<b>CHRONIC CONDITION</b> causing: • ≥ 3 hospital admissions in the last year • ≥ 4 weeks continuous admission for current inpatients.	
<b>CONGESTIVE HEART FAILURE</b> with symptoms at rest or on minimal exertion.	
<b>CHRONIC LUNG DISEASE</b> with symptoms at rest or on minimal exertion.	
Severe and irreversible <b>NEUROLOGICAL CONDITION</b> including moderate to severe dementia.	
<b>CHRONIC LIVER DISEASE</b> with Child-Pugh score ≥ 7.	
<b>END STAGE CHRONIC RENAL FAILURE</b> requiring renal replacement therapy.	
<b>MALIGNANCY</b> haematological or metastatic with distance metastases	
<b>IMMUNOCOMPROMISE</b> congenital, acquired, or secondary to Rx (last 6/12)	

Note (i) this is not a ranked list, and (ii) inclusion on list does not imply equal weighting.

### Outcomes in critical care

AGE	DIED
16-39	22.1%
40-49	26.6%
50-59	42.3%
60-69	57.4%
70-79	68.6%
80+	67.3%

Source: [www.icnarc.org](http://www.icnarc.org)  
Interim data 17 Apr 2020 showing deaths to date of report, not final mortality

### Caveat: interpretation of frailty scale in people under 65, or in those of any age with stable disability

The Clinical Frailty Score is a global clinical measure of frailty in older people, reflecting a lifelong accumulation of physiological insults that leads to reduced physiological reserves, associated with poor outcomes.

It has not been validated for use on people under the age of 65, and when used in this context, is more likely to reflect a person's disability.

Therefore individual assessments must be made on the case of people under 65, or those of any age with stable disability (e.g. cerebral palsy) and learning disabilities or autism. In these contexts, dependency on carers or diminished ability to mobilise or exercise may not be an accurate indicator of poor biological reserve or capacity to recover from acute illness.

### Outcomes in critical care

Any severe comorbidity*	Died (COVID-19 2020 to date)	Died (viral pneumonia 2017-19)
No	50.2%	19.3%
Yes	60.7%	33.9%

\*Indicative information only, list of conditions may differ.  
Source: [www.icnarc.org](http://www.icnarc.org)

Interim data 17 Apr 2020 showing deaths to date of report, not final mortality

### Use decision support aid + clinical judgement to assess likely outcome:

Expected to survive	/	Likely to survive	/	Outcome uncertain	/	Not Likely to survive	/	Not expected to survive
---------------------	---	-------------------	---	-------------------	---	-----------------------	---	-------------------------

Apply in the context of a recognised decision-making frameworks<sup>1,2</sup> to identify, communicate and document treatment goals, alternative treatment options, timeline for review of goals, and additional support requirements. Ensure current CRITCON-PANDEMIC level is accurate, and seek colleague and Trust support as needed.

1. <https://www.nice.org.uk/guidance/ng159> (accessed 20 Apr 2020)  
2. [www.criticalcare.nice.org](http://www.criticalcare.nice.org) (accessed 20 Apr 2020)

**Intensive Care Society** | Churchill House | 35 Red Lion Square | London | WC1R 4SG  
T: +44 (0)20 7280 4350 E: [info@ics.ac.uk](mailto:info@ics.ac.uk) W: [www.ics.ac.uk](http://www.ics.ac.uk)

Registered as a Company limited by Guarantee  
Registered No: 2940178 (England) Registered Office as above  
Registered as a Charity in England and Wales No: 1039236 and in Scotland No: SC040052

© Intensive Care Society